Join Growin Stock Community!

Revelation biosciences, inc.REVB.US Overview

US StockHealthcare
(No presentation for REVB)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

REVB AI Insights

REVB Overall Performance

REVB AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

REVB Recent Performance

-1.43%

Revelation biosciences, inc.

0.05%

Avg of Sector

-0.31%

S&P500

REVB PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

REVB Key Information

REVB Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

REVB Profile

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.

Price of REVB

REVB FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

REVB Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.02
PE Ratio (TTM)
0.00
Forward PE
-
PS Ratio (TTM)
2.88
PB Ratio
0.31
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.02
PE Ratio (TTM)
0.00
Forward PE
-
PS Ratio (TTM)
2.88
PB Ratio
0.31
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is REVB's latest earnings report released?

    The most recent financial report for Revelation biosciences, inc. (REVB) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating REVB's short-term business performance and financial health. For the latest updates on REVB's earnings releases, visit this page regularly.

  • How much debt does REVB have?

    As of the end of the reporting period, Revelation biosciences, inc. (REVB) had total debt of 746.78K, with a debt ratio of 0.06. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does REVB have?

    At the end of the period, Revelation biosciences, inc. (REVB) held Total Cash and Cash Equivalents of 10.7M, accounting for 0.92 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is REVB's EPS continuing to grow?

    According to the past four quarterly reports, Revelation biosciences, inc. (REVB)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 15.05. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of REVB?

    Revelation biosciences, inc. (REVB)'s Free Cash Flow (FCF) for the period is -1.97M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 47.26% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of REVB?

    The latest valuation data shows Revelation biosciences, inc. (REVB) has a Price-To-Earnings (PE) ratio of -0.33 and a Price/Earnings-To-Growth (PEG) ratio of 0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.